114351-06-3

Upstream product

• 621-82-9 Cinnamic acid 
• 114350-89-9 4-hydroxy-2-(1-hydroxypropyl)-N-(2-thiazolyl)-8-trifluoromethyl-3-quinoline-carboxamide 
• 2719-23-5 2-acetamidothiazole 
• 114351-29-0 2-[(2-chloro-1-oxo-butyl)-amino]-β-oxo-N-(2-thiazolyl)-3-trifluoromethyl-benzenepropanamide 
• 114351-39-2 1,3-dihydro-3-ethyl-1-[(2-thiazolyl)-imino]-5-(trifluoromethyl)-furo-[3,4-b]-quinolin-9-ol 
• 114351-20-1 2-(1-chloropropyl)-8-trifluoromethyl-4H-3,1-benzoxazine-4-one 

Relevant academic research and scientific papers

4-hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities

A series of 4-hydroxy-3-quinolinecarboxamides has been synthesized and evaluated by the oral route as antiinflammatory agents in carrageenin-induced foot edema and adjuvant-induced arthritis and as analgesic agents in the acetic acid induced writhing test. Among the most active molecules, some have shown both analgesic and acute antiinflammatory activities. Others, such as compounds 24, 37, and 52, were only powerful peripherally acting analgesics. Compound 52, being active at 1 mg/kg (ED50), is the most potent compound in the series. Some analogues, substituted in the 2-position by an alcohol, ester, or amine function, displayed potent antiarthritic activity in the same range as that of piroxicam and were also active in acute tests of inflammation and nociception. They inhibited the activity of both cyclooxygenase and 5-lipoxygenase at micromolar concentrations. Compound 102 (RU 43526) showed potent antiarthritic activity (adjuvant-induced arthritis, ED50 = 0.7 mg/kg, po), and gastrointestinal tolerance (ED100 250 mg/kg, po) and thus it is presently undergoing an extensive pharmacological evaluation.

Novel 4-hydroxy-3-quinoline-carboxylates having analgesic and anti-inflammatory activity

Novel optical isomers and racemates of 4-hydroxy-3-quinoline-carboxylates of the formula STR1 wherein X is in the 5-, 6-, 7- or 8-position and is selected from the group consisting of hydrogen, halogen, alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 4 carbon atoms, --CF3, --SCF3 and --OCF3, R1 is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, R2 is selected from the group consisting of thiazolyl, 4,5-dihydrothiazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, pyrimidyl and tetrazolyl all optionally substituted with alkyl of 1 to 4 carbon atoms and phenyl substituted with at least one member of the group consisting of --OH, alkyl and alkoxy of 1 to 4 carbon atoms, --CF3, --NO2 and halogen, R3 and R4 are individually selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and aryl, R5 is selected from the group consisting of aryl of 6 to 14 carbon atoms, heteroaryl of 3 to 14 carbon atoms, alkyl of 1 to 14 carbon atoms, alkyl substituted with --NH2, --NHAlk or STR2 alkenyl of 2 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms substituted with aryl of 6 to 14 carbon atoms, Alk and Alk' are alkyl of 1 to 6 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts with the proviso that when X is 8-CF3, R1 and R3 are hydrogen, R2 is 2-thiazolyl, R4 is methyl, R5 is not methyl having analgesic and anti-inflammatory activity.